Blood plasma is a yellowish liquid component of blood that holds the blood cells of whole blood in suspension. It is the liquid part of the blood that carries cells and proteins throughout the body. It makes up about 55% of the body's total blood volume. It is the intravascular fluid part of extracellular fluid (all body fluid outside cells). It is mostly water (up to 95% by volume), and contains important dissolved proteins (6–8%) (e.g., serum albumins, globulins, and fibrinogen), glucose, clotting factors, electrolytes (Na+, Ca2+, Mg2+, HCO3−, Cl−, etc.), hormones, carbon dioxide (plasma being the main medium for excretory product transportation), and oxygen. It plays a vital role in an intravascular osmotic effect that keeps electrolyte concentration balanced and protects the body from infection and other blood disorders.
Blood plasma is separated from the blood by spinning a tube of fresh blood containing an anticoagulant in a centrifuge until the blood cells fall to the bottom of the tube. The blood plasma is then poured or drawn off. For point-of-care testing applications, plasma can be extracted from whole blood via filtration or via agglutination to allow for rapid testing of specific biomarkers. Blood plasma has a density of approximately 1025 kg/m3, or 1.025 g/ml.
Plasmapheresis is a medical therapy that involves blood plasma extraction, treatment, and reintegration.
Fresh frozen plasma is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. It is of critical importance in the treatment of many types of trauma which result in blood loss, and is therefore kept stocked universally in all medical facilities capable of treating trauma (e.g., trauma centers, hospitals, and ambulances) or that pose a risk of patient blood loss such as surgical suite facilities.
Blood plasma volume may be expanded by or drained to extravascular fluid when there are changes in Starling forces across capillary walls. For example, when blood pressure drops in circulatory shock, Starling forces drive fluid into the interstitium, causing third spacing.
Standing still for a prolonged period will cause an increase in transcapillary hydrostatic pressure. As a result, approximately 12% of blood plasma volume will cross into the extravascular compartment. This causes an increase in hematocrit, serum total protein, blood viscosity and, as a result of increased concentration of coagulation factors, it causes orthostatic hypercoagulability.
Albumins are the most common plasma proteins and they are responsible for maintaining the osmotic pressure of blood. Without albumins, the consistency of blood would be closer to that of water. The increased viscosity of blood prevents fluid from entering the bloodstream from outside the capillaries.
The second most common type of protein in the blood plasma are globulins. Important globulins include immunoglobins which are important for the immune system and transport hormones and other compounds around the body.
Fibrinogen proteins make up most of the remaining proteins in the blood. Fibrinogens are responsible for clotting blood to help prevent blood loss.
Plasma is normally yellow due to bilirubin, carotenoids, hemoglobin and transferrin. In abnormal cases, plasma can have varying shades of orange, green or brown. Green color can be due to ceruloplasmin or sulfhemoglobin. Latter may form due to medicines that are able to form sulfonamides once ingested (see sulfhemoglobinemia). Dark brown or reddish color can appear due to hemolysis, in which methemoglobin is released from broken blood cells (see methemoglobinemia). Plasma is normally relatively transparent, but sometimes it can be opaque. Opaqueness is typically due to elevated content of lipids like cholesterol and triglycerides (see hyperlipidemia).
Plasma vs serum in medical diagnostics
Blood plasma and blood serum are often used in blood tests. Some tests can be done only on plasma and some only on serum. Some can be done on both, but depending on the test, use of either plasma or serum can be more practical. In addition, some tests have to be done with whole blood, such as the determination of the amount of blood cells in blood via flow cytometry.
|Some of the benefits of plasma over serum||Some of the benefits of serum over plasma|
|Plasma preparation is quick, as it is not coagulated. Serum sample preparation requires about 30 minutes of waiting time before it can be centrifuged and then analyzed. However, coagulation can be hastened down to a few minutes by adding thrombin or similar agents to the serum sample.||Plasma preparation requires the addition of anticoagulants, which can cause expected and unexpected measurement errors. For example, anticoagulant salts can add extra cations like NH4+, Li+, Na+ and K+ to the sample, or impurities like lead and aluminum. Chelator anticoagulants like EDTA and citrate salts work by binding calcium (see carboxyglutamic acid), but they may also bind other ions. Even if such ions are not the analytes, chelators can interfere with enzyme activity measurements. For example, EDTA binds zinc ions, which alkaline phosphatases need as cofactors. Thus, phosphatase activity cannot be measured if EDTA is used.|
|Compared to serum, 15–20% larger volume of plasma can be obtained from a blood sample of certain size. Serum lacks some proteins that partake in coagulation and increase the sample volume.||An unknown volume of anticoagulants can be added to a plasma sample by accident, which may ruin the sample as the analyte concentration is changed by an unknown amount.|
|Serum preparation can cause measurement errors by increasing or decreasing the concentration of the analyte that is meant to be measured. For example, during coagulation, blood cells consume blood glucose and platelets increase the sample content of compounds like potassium, phosphates and aspartate transaminase by secreting them. Glucose or these other compounds may be the analytes.||No anticoagulants are added to serum samples, which decreases the preparation cost of the samples relative to plasma samples.|
|Plasma samples can form tiny clots if the added anticoagulant is not properly mixed with the sample. Non-uniform samples can cause measurement errors.|
Plasma was already well known when described by William Harvey in de Mortu Cordis in 1628, but knowledge of it probably extends as far back as Vesalius (1514–1564). The discovery of fibrinogen by William Henson in circa 1770 (ibid.) made it easier to study plasma, as ordinarily, upon coming in contact with a foreign surface – something other than vascular endothelium – clotting factors become activated and clotting proceeds rapidly, trapping RBCs etc. in the plasma and preventing separation of plasma from the blood. Adding citrate and other anticoagulants is a relatively recent advance. Note that, upon formation of a clot, the remaining clear fluid (if any) is Serum (blood), which is essentially plasma without the clotting factors.
The use of blood plasma as a substitute for whole blood and for transfusion purposes was proposed in March 1918, in the correspondence columns of the British Medical Journal, by Gordon R. Ward. "Dried plasmas" in powder or strips of material format were developed and first used in World War II. Prior to the United States' involvement in the war, liquid plasma and whole blood were used.
The Origin of Plasmapheresis
Dr. José Antonio Grifols Lucas, a scientist from Vilanova i la Geltrú, Spain, founded Laboratorios Grifols in 1940. Dr. Grifols pioneered a first-of-its-kind technique called plasmapheresis, where a donor's red blood cells would be returned to the donor's body almost immediately after the separation of the blood plasma. This technique is still in practice today, almost 80 years later. In 1945, Dr. Grifols opened the world's first plasma donation center. Thirteen years after the center's opening, Dr. Grifols unexpectedly died at the young age of 41 due to leukemia.
Blood for Britain
The "Blood for Britain" program during the early 1940s was quite successful (and popular in the United States) based on Charles Drew's contribution. A large project began in August 1940 to collect blood in New York City hospitals for the export of plasma to Britain. Drew was appointed medical supervisor of the "Plasma for Britain" project. His notable contribution at this time was to transform the test tube methods of many blood researchers into the first successful mass production techniques.
Nevertheless, the decision was made to develop a dried plasma package for the armed forces as it would reduce breakage and make the transportation, packaging, and storage much simpler. The resulting dried plasma package came in two tin cans containing 400 cc bottles. One bottle contained enough distilled water to reconstitute the dried plasma contained within the other bottle. In about three minutes, the plasma would be ready to use and could stay fresh for around four hours. The Blood for Britain program operated successfully for five months, with total collections of almost 15,000 people donating blood, and with over 5,500 vials of blood plasma.
Following the "Plasma for Britain" invention, Drew was named director of the Red Cross blood bank and assistant director of the National Research Council, in charge of blood collection for the United States Army and Navy. Drew argued against the armed forces directive that blood/plasma was to be separated by the race of the donor. Drew insisted that there was no racial difference in human blood and that the policy would lead to needless deaths as soldiers and sailors were required to wait for "same race" blood.
By the end of the war the American Red Cross had provided enough blood for over six million plasma packages. Most of the surplus plasma was returned to the United States for civilian use. Serum albumin replaced dried plasma for combat use during the Korean War.
Plasma as a blood product prepared from blood donations is used in blood transfusions, typically as fresh frozen plasma (FFP) or Plasma Frozen within 24 hours after phlebotomy (PF24). When donating whole blood or packed red blood cell (PRBC) transfusions, O- is the most desirable and is considered a "universal donor," since it has neither A nor B antigens and can be safely transfused to most recipients. Type AB+ is the "universal recipient" type for PRBC donations. However, for plasma the situation is somewhat reversed. Blood donation centers will sometimes collect only plasma from AB donors through apheresis, as their plasma does not contain the antibodies that may cross react with recipient antigens. As such, AB is often considered the "universal donor" for plasma. Special programs exist just to cater to the male AB plasma donor, because of concerns about transfusion related acute lung injury (TRALI) and female donors who may have higher leukocyte antibodies. However, some studies show an increased risk of TRALI despite increased leukocyte antibodies in women who have been pregnant.
This section does not cite any sources. (March 2020) (Learn how and when to remove this template message)
Following fears of variant Creutzfeldt-Jakob disease (vCJD) being spread through the blood supply, the British government began[when?] to import plasma (to meet the need for commercially manufactured fractionated plasma medicines) and (through devolved Blood Services) imported plasma from Europe (to meet the needs for plasma blood components for certain patient groups). In 2002, the British government purchased Life Resources Incorporated to import plasma for medicines made from fractionated plasma. The company became Plasma Resources UK (PRUK) which owned Bio Products Laboratory. In 2013, the British government sold an 80% stake in PRUK to American hedge fund Bain Capital, in a deal estimated to be worth £230 million. The sale was met with criticism in the UK.
Currently,[when?] blood donated in the United Kingdom is used by UK Blood Services for the manufacture of plasma blood components (Fresh Frozen Plasma (FFP) and cryoprecipitate). However, plasma from UK donors is still not used for the commercial manufacture of fractionated plasma medicines.
Synthetic blood plasma
Simulated body fluid (SBF) is a solution having a similar ion concentration to that of human blood plasma. SBF is normally used for the surface modification of metallic implants, and more recently in gene delivery application.
- Blood plasma fractionation
- Blood proteins
- Chromatography in blood processing
- Hypoxia preconditioned plasma
- Intravascular volume status
- Dennis O'Neil (1999). "Blood Components". Palomar College. Archived from the original on June 5, 2013.
- Tuskegee University (May 29, 2013). "Chapter 9 Blood". tuskegee.edu. Archived from the original on December 28, 2013.
- "Ways to Keep Your Blood Plasma Healthy". Archived from the original on November 1, 2013. Retrieved November 10, 2011.
- Maton, Anthea; Jean Hopkins; Charles William McLaughlin; Susan Johnson; Maryanna Quon Warner; David LaHart; Jill D. Wright (1993). Human Biology and Health. Englewood Cliffs, New Jersey, USA: Prentice Hall. ISBN 0-13-981176-1.
- Tripathi S, Kumar V, Prabhakar A, Joshi S, Agrawal A (2015). "Passive blood plasma separation at the microscale: a review of design principles and microdevices". J. Micromech. Microeng. 25 (8): 083001. Bibcode:2015JMiMi..25h3001T. doi:10.1088/0960-1317/25/8/083001.
- Guo, Weijin; Hansson, Jonas; van der Wijngaart, Wouter (2020). "Synthetic Paper Separates Plasma from Whole Blood with Low Protein Loss". Analytical Chemistry. 92 (9): 6194–6199. doi:10.1021/acs.analchem.0c01474. ISSN 0003-2700. PMID 32323979.
- The Physics Factbook – Density of Blood
- "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
- Masoud M, Sarig G, Brenner B, Jacob G (June 2008). "Orthostatic hypercoagulability: a novel physiological mechanism to activate the coagulation system". Hypertension. 51 (6): 1545–51. doi:10.1161/HYPERTENSIONAHA.108.112003. PMID 18413485.
- Basic Biology (2015). "Blood cells".
- Elkassabany NM, Meny GM, Doria RR, Marcucci C (2008). "Green Plasma—Revisited". Anesthesiology. 108 (4): 764–765. doi:10.1097/ALN.0b013e3181672668. PMID 18362615.
- Mani A, Poornima AP, Gupta D (2019). "Greenish discoloration of plasma: Is it really a matter of concern?". Asian Journal of Transfusion Science. 13 (1): 1–2. doi:10.4103/ajts.AJTS_117_18. PMC 6580839. PMID 31360002.
- Tesfazghi MT, McGill MR, Yarbrough ML (2019). "What's Causing This Dark Brown Plasma?". The Journal of Applied Laboratory Medicine. 4 (1): 125–129. doi:10.1373/jalm.2018.026633. PMID 31639715.
- Agnihotri N, Kumar L (2014). "Turbid plasma donations: Need for quantification". Asian Journal of Transfusion Science. 8 (2): 78–79. doi:10.4103/0973-6247.137436. PMC 4140067. PMID 25161342.
- "Use of anticoagulants in diagnostic laboratory investigations". World Health Organization. 2002. hdl:10665/65957. WHO/DIL/LAB/99.1 Rev.2.
- Jimenez VE, Chew Y, Nicholson L, Burns H, Anderson P, Chen H, Williams L, Keung K, Zanjani NT, Dervish S, Patrick E (2019). "Standardisation of flow cytometry for whole blood immunophenotyping of islet transplant and transplant clinical trial recipients". PLOS ONE. 14 (5): e0217163. Bibcode:2019PLoSO..1417163J. doi:10.1371/journal.pone.0217163. PMC 6530858. PMID 31116766.
- Kocijancic M, Cargonja J, Delic-Knezevic A (2014). "Evaluation of the BD Vacutainer® RST blood collection tube for routine chemistry analytes: clinical significance of differences and stability study". Biochemia Medica. 24 (3): 368–375. doi:10.11613/BM.2014.039. PMC 4210257. PMID 25351355.
- Uges D (1988). "Plasma or serum in therapeutic drug monitoring and clinical toxicology". Pharmaceutisch Weekblad. 10 (5): 185–188. doi:10.1007/BF01956868. PMID 3060834. S2CID 32330414.
- Wintrobe. Blood, Pure and Eloquent.
- "When a Dream Comes True". grifols.com. January 2015.
- "Biography: J.A. Grifols". discovertheplasma.com.
- Transfusion before World War I
- Plasma Equipment and Packaging, and Transfusion Equipment
- Starr, Douglas P. (2000). Blood: An Epic History of Medicine and Commerce. New York: Quill. ISBN 0-688-17649-6.
- Hirsch, Eric (1991). What Your 1st Grader Needs to Know: Fundamentals of a Good First-Grade Education. pp 232–233. New York: Doubleday.
- The Plasma Program
- "AB Plasma Donor Program". NIH Clinical Center. March 20, 2008. Retrieved March 18, 2011.
- "Female Plasma May Not Increase Risk for Transfusion-Related Acute Lung Injury". Medscape. October 23, 2007. Retrieved July 2, 2011.